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Variants of the apolipoprotein L1 (APOL1) gene have been
linked to a variety of renal diseases in individuals of African
ancestry including focal segmental glomerulosclerosis and
hypertension-attributed nephropathy (1). Two common
coding variants in the APOL1gene (G1 and G2), known to
impart resistance to Trypanosoma infections, appear to
confer most of the renal-associated risk. Patients with two
copies of the coding variants are at highest risk while those
with one allele have similar risk to patients with zero
alleles (2). TheAPOL1 risk alleles are common in individuals
of African ancestry occurring in more than 30% of
chromosomes but are very rare in those of European
descent (<1%) (1). In both the African American Study of
Kidney Disease and Hypertension and in the Chronic Renal
Insufficiency Cohort study, African American patients with
two variants had approximately a 1.5 to 2-fold increased risk
for end-stage renal disease or doubling of creatinine and
more rapid rate of CKD progression compared to thosewith
zero or one allele (2).
These nontransplant studies on APOL1 provide a compel-
ling rationale to examine whether the APOL1 risk effects
explain partly or fully, the well-established inferior allograft
survival seen in African American recipients or in thosewho
receive African American donor kidneys. In a small study
involving 119 African American kidney transplant recipi-
ents, Lee et al found no difference in graft survival in high-
risk APOL1 (two alleles) compared to low-risk (zero or one
allele) recipients (HR 0.96; 95% CI 0.61–1.49; p¼0.84) (3).
In a single center study from North Carolina, Reeves-Daniel
et al examined outcomes from 106 African American
deceased donors, of whom 22 (21%) had two APOL1
copies, and found that two APOL1 variants in a deceased
donor was independently associated with a greater risk of
graft failure (HR 3.84; p¼ 0.0.84) (4). In this issue of AJT,
Freedman et al follow-up on this original report from North
Carolina by including new deceased donors from their state
as well as from Alabama (5). In this analysis, they report
outcomes on 675 kidney transplants performed at 55
centers (two centers accounted for 62% of transplants)
from 368 African American deceased donors. The trans-
plants spanned many years with some being done as early
as 2001 while approximately 25% were performed after
2010. Of the 675 transplants, 99 (15%) were from donors
with two APOL1 risk variants and during follow-up 24 of
these 99 (24%) failed. In an adjusted model involving the
entire cohort, recipients who received a donor kidney with
twoAPOL1 alleles had over a twofold increased risk of graft
failure (HR 2.26; 95% CI 1.37–3.74; p¼ 0.001). Despite a
larger sample (n¼ 221), two APOL1 alleles was not
independently associated with graft loss in recipients of
Alabama donor kidneys (HR 2.71; 95% CI 0.95–7.69) while
it was in the original cohort of 127 patients from North
Carolina (HR 2.33; 95% CI 1.10–4.90). Examination of the
survival curves reveals that most grafts failed within the
first 2 years posttransplantation, although APOL1 risk
variants were not associated with delayed graft function or
acute rejection.
What shouldwemake of this data? The authors suggestwe
genotype deceased donors for APOL1 and use this
information to guide allocation and informed consent.
This recommendation is premature and is not supported by
the research findings in themanuscript by Freedman et al or
other published work. It is also potentially injurious to
African American transplant candidates who may receive
fewer transplants if such donor kidneys are excluded. We
believe that the article by Freedman et al raises more
questions than it answered. The limitations diminish the
weight of evidence towarrant recommending usingAPOL1
risk status to inform deceased donor organ allocation. First,
it remains unknownwhy these allografts failed. Could these
graft losses be due to unrecognized antibody injury or some
other insult such as BK virus infection? In this regard,
allograft biopsy data would be critically informative.
Perhaps recipients of donors with two APOL1 variants
just need heightened surveillance to prevent or quickly treat
a ‘‘second hit’’ such as an infection or rejection. Second,
when the analysiswas further adjusted by including time on
dialysis, recipient diabetes status and BMI the HR for graft
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loss fell from 2.26 to 1.99 suggesting confounding and the
possibility of residual confounding cannot be excluded.
Thirdly, recipient APOL1 genotyping was not available and
despite the previously mentioned negative findings (3) an
interaction between donor and recipient risk variants
cannot be excluded. Fourth, the study showed an associa-
tion with APOL1 risk variants which is not the same as
causality. It is possible that other genes may be directly
involved in the cascade of events leading to graft failure.
Finally, the number of graft losses in the entire APOL1 high
risk group was only 24 and follow-up beyond 2 years
occurred in a very small number of patients.
The retrospective analysis by Freedman et al has not
produced evidence to support the use of APOL1 genotyp-
ing in deceased donor transplantation because of the
inherent limitations of the study noted above. The next step
forward should be a geographically broader, multi-center,
prospective cohort study to obtain highly granular pheno-
type data to answer the unresolved questions. To be
methodologically rigorous, the optimal study would include
all consecutive donors at several distinct OPOs and the
analysis should take into account information on immuno-
suppression, preimplantation biopsies, posttransplant com-
plications (e.g. infections), donor specific antibody using
modern solid phase assays, and biopsies for cause to
determine the precise phenotype of the grafts that fail with
two APOL1 risk variants. Only with such a rigorous study
can we precisely define the true impact of APOL1 renal risk
variants on allograft survival. Premature use of this data to
guide kidney allocation is decidedly unwarranted and is
likely to disadvantage African American patients waiting
for a transplant, result in more discards, and contribute to
lower wait list survival for those who should have been
transplanted.
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